# S0341: Erlotinib in Treating Patients With Advanced Primary Non-Small Cell Lung Cancer

> **NCT00087412** · PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 65 (actual)

## Conditions studied

- Adenocarcinoma of the Lung
- Large Cell Lung Cancer
- Recurrent Non-small Cell Lung Cancer
- Squamous Cell Lung Cancer
- Stage IIIB Non-small Cell Lung Cancer
- Stage IV Non-small Cell Lung Cancer

## Interventions

- **DRUG:** erlotinib hydrochloride
- **OTHER:** laboratory biomarker analysis

## Key facts

- **NCT ID:** NCT00087412
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-09
- **Primary completion:** 2007-07
- **Final completion:** —
- **Target enrollment:** 65 (ACTUAL)
- **Last updated:** 2013-02-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00087412

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00087412, "S0341: Erlotinib in Treating Patients With Advanced Primary Non-Small Cell Lung Cancer". Retrieved via AI Analytics 2026-07-17 from https://api.ai-analytics.org/clinical/NCT00087412. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*